Levodopa-induced dyskinesias in Parkinson’s disease increase cerebrospinal fluid nitric oxide metabolites’ levels

Author(s):  
Bruno L. Santos-Lobato ◽  
Mariza Bortolanza ◽  
Lucas César Pinheiro ◽  
Marcelo E. Batalhão ◽  
Ângela V. Pimentel ◽  
...  
2020 ◽  
Author(s):  
Bruno L. Santos-Lobato ◽  
Mariza Bortolanza ◽  
Marcelo E. Batalhão ◽  
Ângela V. Pimentel ◽  
Evelin Capellari-Carnio ◽  
...  

AbstractIntroductionLevodopa-induced dyskinesias (LID) in Parkinson’s disease (PD) are frequent complications, and nitric oxide has a role on its pathophysiology. The present work aims to investigate CSF levels of nitric oxide metabolites nitrite and nitrate (NOx) in patients with PD and LID.MethodsWe measured CSF NOx levels in patients with PD with and without LID, and in healthy controls. The levels of CSF NOx levels were measured by ozone-based chemiluminescence.Results67 participants were enrolled. CSF NOx levels were higher in patients with PD with LID than in healthy controls (Kruskal-Wallis statistics = 7.24, p = 0.02). CSF NOx levels did not correlate with other clinical variables.ConclusionWe reported higher levels of nitric oxide in the CSF of patients with PD and LID.Highlights–Nitric oxide has a role on levodopa-induced dyskinesias in Parkinson’s disease–We measured CSF nitrite and nitrate in Parkinson’s disease patients with dyskinesias–CSF nitrite and nitrate were higher in Parkinson’s disease patients with dyskinesias


2016 ◽  
Vol 23 (24) ◽  
pp. 2666-2679 ◽  
Author(s):  
Félix Jiménez-Jiménez ◽  
Hortensia Alonso-Navarro ◽  
María Herrero ◽  
Elena García-Martín ◽  
José Agúndez

2021 ◽  
Author(s):  
Thomas Kremer ◽  
Kirsten I. Taylor ◽  
Juliane Siebourg‐Polster ◽  
Thomas Gerken ◽  
Andreas Staempfli ◽  
...  

2021 ◽  
Author(s):  
Feng Han ◽  
Gregory L. Brown ◽  
Yalin Zhu ◽  
Aaron E. Belkin‐Rosen ◽  
Mechelle M. Lewis ◽  
...  

2013 ◽  
Vol 28 (6) ◽  
pp. 747-754 ◽  
Author(s):  
Karin D. van Dijk ◽  
Emanuele Persichetti ◽  
Davide Chiasserini ◽  
Paolo Eusebi ◽  
Tommaso Beccari ◽  
...  

Biomedicines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 491
Author(s):  
Joaquín Fernández-Irigoyen ◽  
Paz Cartas-Cejudo ◽  
Marta Iruarrizaga-Lejarreta ◽  
Enrique Santamaría

Lipid metabolism is clearly associated to Parkinson’s disease (PD). Although lipid homeostasis has been widely studied in multiple animal and cellular models, as well as in blood derived from PD individuals, the cerebrospinal fluid (CSF) lipidomic profile in PD remains largely unexplored. In this study, we characterized the post-mortem CSF lipidomic imbalance between neurologically intact controls (n = 10) and PD subjects (n = 20). The combination of dual extraction with ultra-performance liquid chromatography-electrospray ionization quadrupole-time-of-flight mass spectrometry (UPLC-ESI-qToF-MS/MS) allowed for the monitoring of 257 lipid species across all samples. Complementary multivariate and univariate data analysis identified that glycerolipids (mono-, di-, and triacylglycerides), saturated and mono/polyunsaturated fatty acids, primary fatty amides, glycerophospholipids (phosphatidylcholines, phosphatidylethanolamines), sphingolipids (ceramides, sphingomyelins), N-acylethanolamines and sterol lipids (cholesteryl esters, steroids) were significantly increased in the CSF of PD compared to the control group. Interestingly, CSF lipid dyshomeostasis differed depending on neuropathological staging and disease duration. These results, despite the limitation of being obtained in a small population, suggest extensive CSF lipid remodeling in PD, shedding new light on the deployment of CSF lipidomics as a promising tool to identify potential lipid markers as well as discriminatory lipid species between PD and other atypical parkinsonisms.


2018 ◽  
Vol 8 (4) ◽  
pp. 52 ◽  
Author(s):  
Manuel Menéndez-González ◽  
Huber Padilla-Zambrano ◽  
Cristina Tomás-Zapico ◽  
Benjamin García

Sign in / Sign up

Export Citation Format

Share Document